The estimated Net Worth of Kevin Rakin is at least $693 ezer dollars as of 21 March 2022. Mr. Rakin owns over 10,000 units of Oramed Pharmaceuticals, Inc stock worth over $111,053 and over the last 10 years he sold ORMP stock worth over $536,989. In addition, he makes $44,648 as Independent Chairman of the Board at Oramed Pharmaceuticals, Inc.
Sign up
Mr. Rakin ORMP stock SEC Form 4 insiders trading
Kevin has made over 5 trades of the Oramed Pharmaceuticals, Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ORMP stock worth $94,100 on 21 March 2022.
The largest trade he's ever made was exercising 79,136 units of Oramed Pharmaceuticals, Inc stock on 9 August 2021 worth over $549,995. On average, Kevin trades about 5,126 units every 106 days since 2014. As of 21 March 2022 he still owns at least 46,661 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Mr. Rakin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Rakin biography
Kevin L. Rakin is Independent Chairman of the Board of the Company. Mr. Rakin is a co-founder and partner at HighCape Partners, a growth equity life sciences fund where he has served since 2013. From June 2011 to November 2012, Mr. Rakin was the President of Regenerative Medicine at Shire plc (“Shire”), a leading specialty biopharmaceutical company. Prior to joining Shire, Mr. Rakin served as the Chairman and Chief Executive Officer of Advanced BioHealing, Inc. from 2007 until its acquisition by Shire for $750 million in June 2011. Mr. Rakin currently serves on the boards of number of private companies. Mr. Rakin holds an MBA from Columbia University and received his graduate and undergraduate degrees in Commerce from the University of Cape Town, South Africa.
What is the salary of Kevin Rakin?
As the Independent Chairman of the Board of Oramed Pharmaceuticals, Inc, the total compensation of Kevin Rakin at Oramed Pharmaceuticals, Inc is $44,648. There are 10 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of $1,551,100.
How old is Kevin Rakin?
Kevin Rakin is 60, he's been the Independent Chairman of the Board of Oramed Pharmaceuticals, Inc since 2017. There are 4 older and 10 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
What's Kevin Rakin's mailing address?
Kevin's mailing address filed with the SEC is 36 Church Ln, Westport, CT 06880, USA.
Insiders trading at Oramed Pharmaceuticals, Inc
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank és Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
What does Oramed Pharmaceuticals, Inc do?
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
What does Oramed Pharmaceuticals, Inc's logo look like?
Complete history of Mr. Rakin stock trades at Oramed Pharmaceuticals, Inc
Oramed Pharmaceuticals, Inc executives and stock owners
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:
-
Nadav Kidron,
President, Chief Executive Officer, Director -
Nadav Kidron Esq.,
Pres, CEO & Exec. Director -
Miriam Kidron,
Chief Scientific Officer, Director -
Joshua Hexter,
Chief Operating and Business Officer -
Dr. Miriam Kidron Ph.D.,
Chief Scientific Officer & Director -
Dr. Miriam Kidron,
Chief Scientific Officer & Director -
Michael Rabinowitz,
Chief Commercial Officer -
Joshua Hexter,
Chief Operating & Bus. Officer -
David Silberman,
CFO, Treasurer & Sec. -
Avraham Gabay,
Chief Financial Officer, Treasurer, Secretary -
Kevin Rakin,
Independent Chairman of the Board -
Leonard Sank,
Independent Director -
Arie Mayer,
Independent Director -
Xiaoming Gao,
Independent Director -
Aviad Friedman,
Independent Director -
Dr. Roy Eldor M.D., Ph.D.,
Chief Medical Advisor & Member of the Scientific Advisory Board -
Daniel Aghion,
Director -
Capital Management Lp Regal...,
-
Xiaopeng Li,
Director -
David Mark Slager,
Director -
Harold Jacob,
Director -
Gerald M Ostrov,
Director -
Capital Management Lp Regals,
10% owner -
Ronald Edward Law,
Chief Strategy Officer -
Michael Berelowitz,
Director -
Yifat Hen Zommer,
CFO, Treasurer and Secretary -
Hilla Eisenberg,
CFO, Treasurer and Secretary -
David Silberman,
Chief Financial Officer -
Mark Daniel Hasleton,
VP Business Development -
Michael Rabinowitz,
Chief Commercial Officer -
Chaime Orlev,
CFO, TREASURER AND SECRETARY -
Benjamin Shapiro,
Director -
Michael Rabinowitz,
Chief Commercial Officer -
Netanel Derovan,
Chief Legal Officer -
Yadin Rozov,
Director -
Yehuda Reznick,
Director